Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) just unveiled an announcement.
Clarity Pharmaceuticals has announced the date for its Annual General Meeting, set for November 25, 2025. This meeting will provide an opportunity for shareholders to receive updates on the company’s progress and future plans, with further details to be communicated in a forthcoming Notice of Meeting.
The most recent analyst rating on (AU:CU6) stock is a Buy with a A$5.70 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company specializing in the development of innovative treatments for serious diseases, particularly focusing on cancer. The company is a leader in the field of radiopharmaceuticals, utilizing its SAR Technology Platform to develop Targeted Copper Theranostics.
Average Trading Volume: 3,314,538
Technical Sentiment Signal: Buy
Current Market Cap: A$1.34B
Learn more about CU6 stock on TipRanks’ Stock Analysis page.